|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DIBENZEPIN HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: JLN0273S4Z |
| Molecule Type: Small molecule |
| Molecular Formula: C18H22ClN3O |
| Molecular Weight: 331.85 |
| AlogP: 2.98 |
| PSA: 26.79 |
| HBD: 0.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase-2 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Arthritis, Rheumatoid; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Rheumatic Diseases
LUMIRACOXIB
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: V91T9204HU |
| Molecule Type: Small molecule |
| Molecular Formula: C15H13ClFNO2 |
| Molecular Weight: 293.73 |
| AlogP: 4.16 |
| PSA: 49.33 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
ETAFEDRINE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Y134VQ304Y |
| Molecule Type: Small molecule |
| Molecular Formula: C12H20ClNO |
| Molecular Weight: 229.75 |
| AlogP: 2.06 |
| PSA: 23.47 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Soluble guanylate cyclase activator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases
PENTAERYTHRITOL TETRANITRATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 10L39TRG1Z |
| Molecule Type: Small molecule |
| Molecular Formula: C5H8N4O12 |
| Molecular Weight: 316.14 |
| AlogP: -1.19 |
| PSA: 209.48 |
| HBD: 0.0 |
| HBA: |
| #RotB: 12.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
PYROGALLOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 01Y4A2QXY0 |
| Molecule Type: Small molecule |
| Molecular Formula: C6H6O3 |
| Molecular Weight: 126.11 |
| AlogP: 0.8 |
| PSA: 60.69 |
| HBD: 3.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tuberculosis
PROTIONAMIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 76YOO33643 |
| Molecule Type: Small molecule |
| Molecular Formula: C9H12N2S |
| Molecular Weight: 180.28 |
| AlogP: 1.67 |
| PSA: 38.91 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Stomatitis; Arthralgia; Myalgia; Rheumatic Diseases; Vaginitis
BENZYDAMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 4O21U048EF |
| Molecule Type: Small molecule |
| Molecular Formula: C19H23N3O |
| Molecular Weight: 309.41 |
| AlogP: 3.42 |
| PSA: 30.29 |
| HBD: 0.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Low Back Pain; Pain; Arthralgia; Myalgia; Rheumatic Diseases
DEXKETOPROFEN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 6KD9E78X68 |
| Molecule Type: Small molecule |
| Molecular Formula: C16H14O3 |
| Molecular Weight: 254.29 |
| AlogP: 3.11 |
| PSA: 54.37 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial penicillin-binding protein inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bacterial Infections
CEFODIZIME
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Z31298J4HQ |
| Molecule Type: Small molecule |
| Molecular Formula: C20H20N6O7S4 |
| Molecular Weight: 584.68 |
| AlogP: 1.0 |
| PSA: 197.4 |
| HBD: 4.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thymidylate synthase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Precursor Cell Lymphoblastic Leukemia-Lymphoma; Adenoma, Bile Duct; Esophageal Neoplasms; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Mesothelioma; Neoplasms
RALTITREXED
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: FCB9EGG971 |
| Molecule Type: Small molecule |
| Molecular Formula: C21H22N4O6S |
| Molecular Weight: 458.5 |
| AlogP: 1.98 |
| PSA: 152.69 |
| HBD: 4.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dental Caries; Osteogenesis Imperfecta; Renal Insufficiency, Chronic; Vitamin D Deficiency; Bipolar Disorder; Giant Cell Tumor of Bone; Giant Cell Tumors; Heart Diseases; Heart Failure; Hyperparathyroidism, Primary; Hypersensitivity; Hypoparathyroidism; Neoplasms; Pancreatic Neoplasms; Parkinson Disease; Pre-Eclampsia; Adenoma; Arthritis, Juvenile; Bone Diseases, Metabolic; Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Fractures, Bone; Hip Fractures; Hyperprolactinemia; Hypertension; Hypocalcemia; Leukemia; Lymphoma; Menopause; Myocardial Ischemia; Obesity; Osteitis Deformans; Osteoporosis; Osteoporosis, Postmenopausal; Ovarian Hyperstimulation Syndrome; Pain; Polycystic Ovary Syndrome; Prostatic Neoplasms, Castration-Resistant
CALCIUM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: SY7Q814VUP |
| Molecule Type: Small molecule |
| Molecular Formula: H2Ca |
| Molecular Weight: 42.09 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
METHAQUALONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 7ZKH8MQW6T |
| Molecule Type: Small molecule |
| Molecular Formula: C16H14N2O |
| Molecular Weight: 250.3 |
| AlogP: 3.0 |
| PSA: 34.89 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid DP receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rosacea; Flushing; Diabetes Mellitus, Type 2; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipid Metabolism Disorders
LAROPIPRANT
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: G7N11T8O78 |
| Molecule Type: Small molecule |
| Molecular Formula: C21H19ClFNO4S |
| Molecular Weight: 435.9 |
| AlogP: 4.39 |
| PSA: 76.37 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
METHYL NICOTINATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 7B1AVU9DJN |
| Molecule Type: Small molecule |
| Molecular Formula: C7H7NO2 |
| Molecular Weight: 137.14 |
| AlogP: 0.87 |
| PSA: 39.19 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bacterial Infections
ROXITHROMYCIN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 21KOF230FA |
| Molecule Type: Small molecule |
| Molecular Formula: C41H76N2O15 |
| Molecular Weight: 837.06 |
| AlogP: 2.21 |
| PSA: 216.89 |
| HBD: 5.0 |
| HBA: |
| #RotB: 13.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium/glucose cotransporter 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Heart Failure; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus
SOTAGLIFLOZIN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 6B4ZBS263Y |
| Molecule Type: Small molecule |
| Molecular Formula: C21H25ClO5S |
| Molecular Weight: 424.95 |
| AlogP: 3.17 |
| PSA: 79.15 |
| HBD: 3.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase-1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Otitis Media; Dysmenorrhea; Fever; Pain
ANTIPYRINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: T3CHA1B51H |
| Molecule Type: Small molecule |
| Molecular Formula: C11H12N2O |
| Molecular Weight: 188.23 |
| AlogP: 1.48 |
| PSA: 26.93 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Pyruvate dehydrogenase kinase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypertension, Pulmonary; Breast Neoplasms; Carcinoma, Squamous Cell; Glioblastoma; Heart Diseases; Lung Neoplasms; Acidosis, Lactic; Pyruvate Dehydrogenase Complex Deficiency Disease
SODIUM DICHLOROACETATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 42932X67B5 |
| Molecule Type: Small molecule |
| Molecular Formula: C2HCl2NaO2 |
| Molecular Weight: 150.92 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
DIBENZEPIN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 510SJZ1Y6L |
| Molecule Type: Small molecule |
| Molecular Formula: C18H21N3O |
| Molecular Weight: 295.39 |
| AlogP: 2.98 |
| PSA: 26.79 |
| HBD: 0.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Melanoma; Atrial Fibrillation; Pulmonary Embolism; Thrombosis
ACENOCOUMAROL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: I6WP63U32H |
| Molecule Type: Small molecule |
| Molecular Formula: C19H15NO6 |
| Molecular Weight: 353.33 |
| AlogP: 3.52 |
| PSA: 110.65 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Schizophrenia; Psychotic Disorders
FLUPHENAZINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: S79426A41Z |
| Molecule Type: Small molecule |
| Molecular Formula: C22H26F3N3OS |
| Molecular Weight: 437.53 |
| AlogP: 4.31 |
| PSA: 29.95 |
| HBD: 1.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Fever; Pain
GLAFENINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 46HL4I09AH |
| Molecule Type: Small molecule |
| Molecular Formula: C19H17ClN2O4 |
| Molecular Weight: 372.81 |
| AlogP: 3.14 |
| PSA: 91.68 |
| HBD: 3.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Infections
HEXETIDINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 852A84Y8LS |
| Molecule Type: Small molecule |
| Molecular Formula: C21H45N3 |
| Molecular Weight: 339.61 |
| AlogP: 4.71 |
| PSA: 32.5 |
| HBD: 1.0 |
| HBA: |
| #RotB: 12.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetic Foot; Acute Kidney Injury; Hypertension
KETANSERIN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 97F9DE4CT4 |
| Molecule Type: Small molecule |
| Molecular Formula: C22H22FN3O3 |
| Molecular Weight: 395.43 |
| AlogP: 2.42 |
| PSA: 75.17 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FERROUS SUCCINATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 818ZYK7N91 |
| Molecule Type: Small molecule |
| Molecular Formula: C4H4FeO4 |
| Molecular Weight: 171.92 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mu opioid receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Heroin Dependence; Opioid-Related Disorders
DIACETYLMORPHINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 70D95007SX |
| Molecule Type: Small molecule |
| Molecular Formula: C21H23NO5 |
| Molecular Weight: 369.42 |
| AlogP: 1.99 |
| PSA: 65.07 |
| HBD: 0.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Acidosis
SODIUM SUCCINATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: P699N4QOWE |
| Molecule Type: Small molecule |
| Molecular Formula: C4H5NaO4 |
| Molecular Weight: 140.07 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
RIMITEROL HYDROBROMIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: I29DRR8S3R |
| Molecule Type: Small molecule |
| Molecular Formula: C12H18BrNO3 |
| Molecular Weight: 304.18 |
| AlogP: 1.27 |
| PSA: 72.72 |
| HBD: 4.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
LEVOMEPROMAZINE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 42BB1Y2586 |
| Molecule Type: Small molecule |
| Molecular Formula: C19H25ClN2OS |
| Molecular Weight: 364.94 |
| AlogP: 4.5 |
| PSA: 15.71 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Digestive System Diseases
ISOMETHEPTENE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Y7L24THH6T |
| Molecule Type: Small molecule |
| Molecular Formula: C9H19N |
| Molecular Weight: 141.26 |
| AlogP: 2.34 |
| PSA: 12.03 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Vertigo
CINNARIZINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 3DI2E1X18L |
| Molecule Type: Small molecule |
| Molecular Formula: C26H28N2 |
| Molecular Weight: 368.52 |
| AlogP: 5.11 |
| PSA: 6.48 |
| HBD: 0.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acne Vulgaris; Bacterial Infections
LYMECYCLINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 7D6EM3S13P |
| Molecule Type: Small molecule |
| Molecular Formula: C29H38N4O10 |
| Molecular Weight: 602.64 |
| AlogP: -0.45 |
| PSA: 242.98 |
| HBD: 9.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases
XANTHINOL NIACINATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8G60H12X2D |
| Molecule Type: Small molecule |
| Molecular Formula: C19H26N6O6 |
| Molecular Weight: 434.45 |
| AlogP: -2.28 |
| PSA: 105.52 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Homocystinuria; Multiple Sclerosis; Bipolar Disorder; Diabetes Mellitus, Type 2; Mental Disorders; Hypertension; Xerostomia
TAURINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 1EQV5MLY3D |
| Molecule Type: Small molecule |
| Molecular Formula: C2H7NO3S |
| Molecular Weight: 125.15 |
| AlogP: -1.17 |
| PSA: 80.39 |
| HBD: 2.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Thrombosis
FLUINDIONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: EQ35YMS20Q |
| Molecule Type: Small molecule |
| Molecular Formula: C15H9FO2 |
| Molecular Weight: 240.23 |
| AlogP: 2.99 |
| PSA: 34.14 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dental Caries
CALCIUM LACTATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 2URQ2N32W3 |
| Molecule Type: Small molecule |
| Molecular Formula: C6H10CaO6 |
| Molecular Weight: 218.22 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |